School of Health Sciences, University of Ioannina, Ioannina, Greece.
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece.
J Diabetes Complications. 2024 Jul;38(7):108781. doi: 10.1016/j.jdiacomp.2024.108781. Epub 2024 May 31.
Pulse wave velocity (PWV) and augmentation index (AIx) are indices used to assess arterial stiffness. We evaluated the effect of sodium glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) on arterial stiffness indices.
We searched PubMed (up to January 2024) for RCTs assessing the effect of SGLT2i or GLP1-RA on arterial stiffness with reporting outcomes PWV and AIx. Effect sizes of the included studies were expressed as weighted mean difference (WMD) and 95 % confidence interval. Subgroup analyses were performed based on comparator (placebo vs. active comparator), design (RCT vs. crossover), population (diabetic vs. all) and blindness (yes vs. no).
A total of 19 studies (SGLT2i, 12 studies; GLP1-RA, 5 studies; SGLT2i/GLP1-RA combination, 2 studies) assessing 1212 participants were included. We did not find any statistically significant association between GLP1-RA or SGLT2i and PWV or AIx. None of the subgroup analyses showed any statistically significant result.
No evidence of a favorable change in arterial stiffness indices (PWV, AIx) was found following the administration of SGLT2i or GLP1-RA.
脉搏波速度(PWV)和增强指数(AIx)是用于评估动脉僵硬度的指标。我们评估了钠-葡萄糖共转运蛋白 2 抑制剂(SGLT2i)和胰高血糖素样肽-1 受体激动剂(GLP1-RA)对动脉僵硬度指标的影响。
我们在 PubMed 上检索了截至 2024 年 1 月评估 SGLT2i 或 GLP1-RA 对 PWV 和 AIx 报告结局的动脉僵硬度影响的 RCT。纳入研究的效应量表示为加权均数差(WMD)和 95%置信区间。根据对照物(安慰剂与活性对照物)、设计(RCT 与交叉)、人群(糖尿病与所有)和盲法(是与否)进行亚组分析。
共纳入 19 项研究(SGLT2i,12 项研究;GLP1-RA,5 项研究;SGLT2i/GLP1-RA 联合治疗,2 项研究),共纳入 1212 名参与者。我们未发现 GLP1-RA 或 SGLT2i 与 PWV 或 AIx 之间存在任何统计学上显著的关联。没有任何亚组分析显示出任何统计学上显著的结果。
在给予 SGLT2i 或 GLP1-RA 后,未发现动脉僵硬度指标(PWV、AIx)有任何有利的变化。